{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:57:13Z","timestamp":1767686233732,"version":"3.48.0"},"reference-count":93,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0131","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:52:31Z","timestamp":1767685951000},"source":"Crossref","is-referenced-by-count":0,"title":["The synergistic treatment of heart and kidney disease"],"prefix":"10.3238","author":[{"given":"Felix","family":"Mahfoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"G\u00f6tzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Kramann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedat","family":"Schwenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"10.3238\/arztebl.m2025.0131_ref1","doi-asserted-by":"crossref","unstructured":"Magnussen C, Ojeda FM, Leong DP, et al.: Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med 2023; 389: 1273\u201385","DOI":"10.1056\/NEJMoa2206916"},{"key":"10.3238\/arztebl.m2025.0131_ref2","doi-asserted-by":"crossref","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296\u2013305","DOI":"10.1056\/NEJMoa041031"},{"key":"10.3238\/arztebl.m2025.0131_ref3","doi-asserted-by":"crossref","unstructured":"Rossing P, Caramori ML, Chan JCN, et al.: KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022; 102: S1\u2013S127","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"10.3238\/arztebl.m2025.0131_ref4","doi-asserted-by":"crossref","unstructured":"Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A: The prevalence of renal failure\u2014results from the German health interview and examination survey for adults, 2008\u20132011 (DEGS1). Dtsch Arztebl Int 2016; 113: 85\u201391","DOI":"10.3238\/arztebl.2016.0085"},{"key":"10.3238\/arztebl.m2025.0131_ref5","doi-asserted-by":"crossref","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, et al.: A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation 2023; 148: 1636\u201364","DOI":"10.1161\/CIR.0000000000001186"},{"key":"10.3238\/arztebl.m2025.0131_ref6","doi-asserted-by":"crossref","unstructured":"Koskinas KC, Van Craenenbroeck EM, Antoniades C, et al.: Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J 2024; 45: 4063\u201398","DOI":"10.1093\/eurheartj\/ehae508"},{"key":"10.3238\/arztebl.m2025.0131_ref7","doi-asserted-by":"crossref","unstructured":"Massie BM, Carson PE, McMurray JJ, et al.: Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456\u201367","DOI":"10.1056\/NEJMoa0805450"},{"key":"10.3238\/arztebl.m2025.0131_ref8","doi-asserted-by":"crossref","unstructured":"Ostrominski JW, Claggett BL, Miao ZM, et al.: Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction. J Am Coll Cardiol 2024; 84: 223\u20138","DOI":"10.1016\/j.jacc.2024.05.005"},{"key":"10.3238\/arztebl.m2025.0131_ref9","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al.: Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024; 391: 1475\u201385","DOI":"10.1056\/NEJMe2410904"},{"key":"10.3238\/arztebl.m2025.0131_ref10","doi-asserted-by":"crossref","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al.: Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383\u201392","DOI":"10.1056\/NEJMoa1313731"},{"key":"10.3238\/arztebl.m2025.0131_ref11","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al.: Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Eng J Med 2022; 387: 1089\u201398","DOI":"10.1056\/NEJMoa2206286"},{"key":"10.3238\/arztebl.m2025.0131_ref12","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al.: Angiotensin\u2014neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381: 1609\u201320","DOI":"10.1056\/NEJMoa1908655"},{"key":"10.3238\/arztebl.m2025.0131_ref13","unstructured":"Bundes\u00e4rztekammer (B\u00c4K) KB (KBV), A der WMF (AWMF): Nationale Versorgungsleitlinie Typ-2-Diabetes \u2013 Langfassung. AWMF 2023. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/nvl-001 (last accessed on 12 September 2025)."},{"key":"10.3238\/arztebl.m2025.0131_ref14","unstructured":"Deutsche Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin (DEGAM) Deutsche Gesellschaft f\u00fcr Nephrologie (DGfN): Versorgung von Patient*innen mit chronischer, nicht-nierenersatztherapiepflichtiger Nierenkrankheit in der Hausarztpraxis. AWMF 2024."},{"key":"10.3238\/arztebl.m2025.0131_ref15","doi-asserted-by":"crossref","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al.: 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41: 1874\u20132071","DOI":"10.1097\/HJH.0000000000003480"},{"key":"10.3238\/arztebl.m2025.0131_ref16","doi-asserted-by":"crossref","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al.: 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024; 45: 3912\u20134018","DOI":"10.1093\/eurheartj\/ehae646"},{"key":"10.3238\/arztebl.m2025.0131_ref17","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al.: SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022; 400 (10354): 757\u201367","DOI":"10.1016\/S0140-6736(22)01429-5"},{"key":"10.3238\/arztebl.m2025.0131_ref18","doi-asserted-by":"crossref","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31\u20139","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"10.3238\/arztebl.m2025.0131_ref19","doi-asserted-by":"crossref","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al.: 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44: 4043\u2013140","DOI":"10.1093\/eurheartj\/ehad192"},{"key":"10.3238\/arztebl.m2025.0131_ref20","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al.: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599\u2013726","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"10.3238\/arztebl.m2025.0131_ref21","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al.: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995\u20132008","DOI":"10.1056\/NEJMoa1911303"},{"key":"10.3238\/arztebl.m2025.0131_ref22","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117\u201328","DOI":"10.1056\/NEJMoa1504720"},{"key":"10.3238\/arztebl.m2025.0131_ref23","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, et al.: Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413\u201324","DOI":"10.1056\/NEJMoa2022190"},{"key":"10.3238\/arztebl.m2025.0131_ref24","doi-asserted-by":"crossref","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al.: SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819\u201329","DOI":"10.1016\/S0140-6736(20)31824-9"},{"key":"10.3238\/arztebl.m2025.0131_ref25","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos G, et al.: Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451\u201361","DOI":"10.1056\/NEJMoa2107038"},{"key":"10.3238\/arztebl.m2025.0131_ref26","doi-asserted-by":"crossref","unstructured":"EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al.: Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388: 117\u201327","DOI":"10.1056\/NEJMoa2204233"},{"key":"10.3238\/arztebl.m2025.0131_ref27","doi-asserted-by":"crossref","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al.: Empagliflozin and progression of kidney disease in type 2 diabetes. N Eng J Med 2016; 375: 323\u201334","DOI":"10.1056\/NEJMoa1515920"},{"key":"10.3238\/arztebl.m2025.0131_ref28","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group: Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med 2025; 392: 777\u201387","DOI":"10.1056\/NEJMoa2409183"},{"key":"10.3238\/arztebl.m2025.0131_ref29","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al.: Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436\u201346","DOI":"10.1056\/NEJMoa2024816"},{"key":"10.3238\/arztebl.m2025.0131_ref30","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al.: 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44: 3627\u201339","DOI":"10.15829\/1560-4071-2023-5168"},{"key":"10.3238\/arztebl.m2025.0131_ref31","doi-asserted-by":"crossref","unstructured":"Ussher JR, Drucker DJ: Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 2023; 20: 463\u201374","DOI":"10.1038\/s41569-023-00849-3"},{"key":"10.3238\/arztebl.m2025.0131_ref32","doi-asserted-by":"crossref","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al.: Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989\u20131002","DOI":"10.1056\/NEJMoa2032183"},{"key":"10.3238\/arztebl.m2025.0131_ref33","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A, et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Eng J Med 2016; 375: 1834\u201344","DOI":"10.1056\/NEJMoa1607141"},{"key":"10.3238\/arztebl.m2025.0131_ref34","doi-asserted-by":"crossref","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al.: Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841\u201351","DOI":"10.1056\/NEJMoa1901118"},{"key":"10.3238\/arztebl.m2025.0131_ref35","doi-asserted-by":"crossref","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.: Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391: 109\u201321","DOI":"10.1056\/NEJMoa2403347"},{"key":"10.3238\/arztebl.m2025.0131_ref36","doi-asserted-by":"crossref","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.: Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Eng J Med 2023; 389: 1069\u201384","DOI":"10.1056\/NEJMc2312296"},{"key":"10.3238\/arztebl.m2025.0131_ref37","doi-asserted-by":"crossref","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.: Semaglutide and cardiovascular outcomes in obesity without diabetes. N Eng J Med 2023; 389: 2221\u201332","DOI":"10.1056\/NEJMoa2307563"},{"key":"10.3238\/arztebl.m2025.0131_ref38","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz \u2013 Langfassung. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/nvl-006 (last accessed on 12 Septmber 2025)."},{"key":"10.3238\/arztebl.m2025.0131_ref39","doi-asserted-by":"crossref","unstructured":"Pitt B, Filippatos G, Agarwal R, et al.: Cardiovascular events with finerenone in kidney disease and type 2 Diabetes. N Engl J Med 2021; 385: 2252\u201363","DOI":"10.1056\/NEJMoa2110956"},{"key":"10.3238\/arztebl.m2025.0131_ref40","doi-asserted-by":"crossref","unstructured":"Neuen BL, Heerspink HJL, Vart P, et al.: Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024; 149: 450\u201362","DOI":"10.1161\/CIRCULATIONAHA.123.067584"},{"key":"10.3238\/arztebl.m2025.0131_ref41","doi-asserted-by":"crossref","unstructured":"Ronco C, McCullough P, Anker SD, et al.: Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality Initiative. Eur Heart J 2010; 31: 703\u201311","DOI":"10.1093\/eurheartj\/ehp507"},{"key":"10.3238\/arztebl.m2025.0131_ref42","doi-asserted-by":"crossref","unstructured":"Bauersachs J, Jaisser F, Toto R: Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 2015; 65: 257\u201363","DOI":"10.1161\/HYPERTENSIONAHA.114.04488"},{"key":"10.3238\/arztebl.m2025.0131_ref43","doi-asserted-by":"crossref","unstructured":"Dicker D, Nguyen G, Abate D, et al.: Global, regional, and national age-sex-specific mortality and life expectancy, 1950\u20132017: A systematic analysis for the global burden of disease study 2017. Lancet 2018; 392: 1684\u2013735","DOI":"10.1016\/S0140-6736(18)31891-9"},{"key":"10.3238\/arztebl.m2025.0131_ref44","doi-asserted-by":"crossref","unstructured":"Murray CJL, Aravkin AY, Zheng P, et al.: Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: A systematic analysis for the global burden of disease study 2019. Lancet 2020; 396: 1223\u201349","DOI":"10.1016\/S0140-6736(20)30752-2"},{"key":"10.3238\/arztebl.m2025.0131_ref45","doi-asserted-by":"crossref","unstructured":"Naghavi M, Ong KL, Aali A, et al.: Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: A systematic analysis for the global burden of disease study 2021. Lancet 2024; 403: 2100\u201332","DOI":"10.1016\/S0140-6736(24)00367-2"},{"key":"10.3238\/arztebl.m2025.0131_ref46","doi-asserted-by":"crossref","unstructured":"Ensminger S, Thiele H, Falk V, Rudolph V: Der Deutsche Herzbericht \u2013 Update 2024\u00a0\u2013 Eine Zusammenfassung der wichtigsten Erkenntnisse. Kardiologie 2024; 18: 476\u201384","DOI":"10.1007\/s12181-024-00715-7"},{"key":"10.3238\/arztebl.m2025.0131_ref47","doi-asserted-by":"crossref","unstructured":"Zhou B, Carrillo-Larco RM, Danaei G, et al.: Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398: 957\u201380","DOI":"10.1016\/S0140-6736(21)01330-1"},{"key":"10.3238\/arztebl.m2025.0131_ref48","doi-asserted-by":"crossref","unstructured":"Jadoul M, Aoun M, Masimango Imani M: The major global burden of chronic kidney disease. Lancet Glob Health 2024; 12: e342\u2013e3","DOI":"10.1016\/S2214-109X(24)00050-0"},{"key":"10.3238\/arztebl.m2025.0131_ref49","doi-asserted-by":"crossref","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, et al.: Global burden of cardiovascular diseases: Projections from 2025 to 2050. Eur J Prev Cardiol 2024; zwae281. doi: 10.1093\/eurjpc\/zwae281. Online ahead of print","DOI":"10.1093\/eurjpc\/zwae281"},{"key":"10.3238\/arztebl.m2025.0131_ref50","doi-asserted-by":"crossref","unstructured":"Ong KL, Stafford LK, McLaughlin SA, et al.: Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the global burden of disease study 2021. Lancet 2023; 402: 203\u201334","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"10.3238\/arztebl.m2025.0131_ref51","doi-asserted-by":"crossref","unstructured":"Alla F, Zannad F, Filippatos G: Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007; 12: 91\u20135","DOI":"10.1007\/s10741-007-9009-2"},{"key":"10.3238\/arztebl.m2025.0131_ref52","doi-asserted-by":"crossref","unstructured":"Rudiger A, Harjola VP, M\u00fcller A, et al.: Acute heart failure: Clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail 2005; 7: 662\u201370","DOI":"10.1016\/j.ejheart.2005.01.014"},{"key":"10.3238\/arztebl.m2025.0131_ref53","doi-asserted-by":"crossref","unstructured":"Jackson CE, Solomon SD, Gerstein HC, et al.: Albuminuria in chronic heart failure: Prevalence and prognostic importance. Lancet 2009; 374: 543\u201350","DOI":"10.1016\/S0140-6736(09)61378-7"},{"key":"10.3238\/arztebl.m2025.0131_ref54","doi-asserted-by":"crossref","unstructured":"Bailey LN, Levitan EB, Judd SE, et al.: Association of urine albumin excretion with incident heart failure hospitalization in community-dwelling adults. JACC Heart Fail 2019; 7: 394\u2013401","DOI":"10.1016\/j.jchf.2019.01.016"},{"key":"10.3238\/arztebl.m2025.0131_ref55","doi-asserted-by":"crossref","unstructured":"Sharma A, Zhao X, Hammill BG, et al.: Trends in noncardiovascular comorbidities among patients hospitalized for heart failure. Circ Heart Fail 2018; 11: e004646","DOI":"10.1161\/CIRCHEARTFAILURE.117.004646"},{"key":"10.3238\/arztebl.m2025.0131_ref56","doi-asserted-by":"crossref","unstructured":"Streng KW, Nauta JF, Hillege HL, et al.: Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol 2018; 271: 132\u20139","DOI":"10.1016\/j.ijcard.2018.04.001"},{"key":"10.3238\/arztebl.m2025.0131_ref57","doi-asserted-by":"crossref","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, et al.: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024; 105: S117\u2013S314","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"10.3238\/arztebl.m2025.0131_ref58","doi-asserted-by":"crossref","unstructured":"Wu HY, Peng YS, Chiang CK, et al.: Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuria screening in patients with diabetes mellitus. JAMA Intern Med 2014; 174: 1108","DOI":"10.1001\/jamainternmed.2014.1363"},{"key":"10.3238\/arztebl.m2025.0131_ref59","doi-asserted-by":"crossref","unstructured":"Schmieder RE, Schutte R, Schumacher H, et al.: Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: An analysis of the ONTARGET and TRANSCEND studies. Diabetologia 2014; 57: 2019\u201329","DOI":"10.1007\/s00125-014-3330-9"},{"key":"10.3238\/arztebl.m2025.0131_ref60","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Mann JF, Yi Q, et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421\u20136","DOI":"10.1001\/jama.286.4.421"},{"key":"10.3238\/arztebl.m2025.0131_ref61","doi-asserted-by":"crossref","unstructured":"Ortiz A, Wanner C, Gansevoort R, et al.: Chronic kidney disease as cardiovascular risk factor in routine clinical practice: A position statement by the Council of the European Renal Association. Eur J Prev Cardiol 2022; 29: 2211\u20135","DOI":"10.1093\/eurjpc\/zwac186"},{"key":"10.3238\/arztebl.m2025.0131_ref62","doi-asserted-by":"crossref","unstructured":"Inker LA, Eneanya ND, Coresh J, et al.: New creatinine\u2014and cystatin C\u2013based equations to estimate GFR without race. N Eng J Med 2021; 385: 1737\u201349","DOI":"10.1056\/NEJMoa2102953"},{"key":"10.3238\/arztebl.m2025.0131_ref63","doi-asserted-by":"crossref","unstructured":"van der Giet M, Nitschmann S: Cystatin C-basierte Sch\u00e4tzung der glomerul\u00e4ren Filtrationsrate. Inn Med 2023; 64: 711\u20134","DOI":"10.1007\/s00108-023-01544-8"},{"key":"10.3238\/arztebl.m2025.0131_ref64","doi-asserted-by":"crossref","unstructured":"Manetti L, Pardini E, Genovesi M, et al.: Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005; 28: 346\u20139","DOI":"10.1007\/BF03347201"},{"key":"10.3238\/arztebl.m2025.0131_ref65","doi-asserted-by":"crossref","unstructured":"Fricker M, Wiesli P, Br\u00e4ndle M, Schwegler B, Schmid C: Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003; 63: 1944\u20137","DOI":"10.1046\/j.1523-1755.2003.00925.x"},{"key":"10.3238\/arztebl.m2025.0131_ref66","doi-asserted-by":"crossref","unstructured":"Risch L, Herklotz R, Blumberg A, Huber AR: Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001; 47: 2055\u20139","DOI":"10.1093\/clinchem\/47.11.2055"},{"key":"10.3238\/arztebl.m2025.0131_ref67","doi-asserted-by":"crossref","unstructured":"George LK, Koshy SKG, Molnar MZ, et al.: Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function. Circ Heart Fail 2017; 10: e003825","DOI":"10.1161\/CIRCHEARTFAILURE.116.003825"},{"key":"10.3238\/arztebl.m2025.0131_ref68","doi-asserted-by":"crossref","unstructured":"El Chamieh C, Liabeuf S, Massy Z: Uremic toxins and cardiovascular risk in chronic kidney disease: What have we learned recently beyond the past findings? Toxins (Basel) 2022; 14: 280","DOI":"10.3390\/toxins14040280"},{"key":"10.3238\/arztebl.m2025.0131_ref69","doi-asserted-by":"crossref","unstructured":"Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A: Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Int J Cardiol 2016; 212: 29\u201336","DOI":"10.1016\/j.ijcard.2016.02.134"},{"key":"10.3238\/arztebl.m2025.0131_ref70","doi-asserted-by":"crossref","unstructured":"Wanner C, Heerspink HJL, Zinman B, et al.: Empagliflozin and kidney function decline in patients with type 2 diabetes: A slope analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol 2018; 29: 2755\u201369","DOI":"10.1681\/ASN.2018010103"},{"key":"10.3238\/arztebl.m2025.0131_ref71","doi-asserted-by":"crossref","unstructured":"Neeland IJ, Ross R, Despr\u00e9s JP, et al.: Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement. Lancet Diabetes Endocrinol 2019; 7: 715\u201325","DOI":"10.1016\/S2213-8587(19)30084-1"},{"key":"10.3238\/arztebl.m2025.0131_ref72","doi-asserted-by":"crossref","unstructured":"Mahabadi AA, Massaro JM, Rosito GA, et al.: Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 2008; 30: 850\u20136","DOI":"10.1093\/eurheartj\/ehn573"},{"key":"10.3238\/arztebl.m2025.0131_ref73","doi-asserted-by":"crossref","unstructured":"Parati G, Esler M: The human sympathetic nervous system: Its relevance in hypertension and heart failure. Eur Heart J 2012; 33: 1058\u201366","DOI":"10.1093\/eurheartj\/ehs041"},{"key":"10.3238\/arztebl.m2025.0131_ref74","doi-asserted-by":"crossref","unstructured":"SPRINT Research Group, Wright JT, Williamson JD, et al.: A randomized trial of intensive versus standard blood-pressure control. N Enl J Med 2015; 373: 2103\u201316","DOI":"10.1056\/NEJMoa1511939"},{"key":"10.3238\/arztebl.m2025.0131_ref75","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL, et al.: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111\u201388","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"10.3238\/arztebl.m2025.0131_ref76","doi-asserted-by":"crossref","unstructured":"Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group: KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303\u20139","DOI":"10.1038\/ki.2014.31"},{"key":"10.3238\/arztebl.m2025.0131_ref77","doi-asserted-by":"crossref","unstructured":"Tunnicliffe DJ, Palmer SC, Cashmore BA, et al.: HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2023; 11: CD007784","DOI":"10.1002\/14651858.CD007784.pub3"},{"key":"10.3238\/arztebl.m2025.0131_ref78","doi-asserted-by":"crossref","unstructured":"Jhund PS, Solomon SD, Docherty KF, et al.: Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: Results of DAPA-HF. Circulation 2021; 143: 298\u2013309","DOI":"10.1161\/CIRCULATIONAHA.120.050391"},{"key":"10.3238\/arztebl.m2025.0131_ref79","doi-asserted-by":"crossref","unstructured":"Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K: SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: A systematic review and meta-analysis. Sci Rep 2023; 13: 15922","DOI":"10.1038\/s41598-023-42989-z"},{"key":"10.3238\/arztebl.m2025.0131_ref80","doi-asserted-by":"crossref","unstructured":"Zannad F: Aldosterone and heart failure. Eur Heart J 1995; 16 (Suppl N): 98\u2013102","DOI":"10.1093\/eurheartj\/16.suppl_N.98"},{"key":"10.3238\/arztebl.m2025.0131_ref81","doi-asserted-by":"crossref","unstructured":"G\u00f6tzinger F, Kunz M, Lauder L, B\u00f6hm M, Mahfoud F: New ways of mitigating aldosterone in cardiorenal disease. Eur Heart J Cardiovasc Pharmacother 2024; 10: 557\u201365","DOI":"10.1093\/ehjcvp\/pvae049"},{"key":"10.3238\/arztebl.m2025.0131_ref82","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Eng J Med 1999; 341: 709\u201317","DOI":"10.1056\/NEJM199909023411001"},{"key":"10.3238\/arztebl.m2025.0131_ref83","doi-asserted-by":"crossref","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309\u201321","DOI":"10.1056\/NEJMoa030207"},{"key":"10.3238\/arztebl.m2025.0131_ref84","doi-asserted-by":"crossref","unstructured":"Zannad F, McMurray JJV, Krum H, et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11\u201321","DOI":"10.1056\/NEJMoa1009492"},{"key":"10.3238\/arztebl.m2025.0131_ref85","doi-asserted-by":"crossref","unstructured":"Currie G, Taylor AHM, Fujita T, et al.: Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis. BMC Nephrol 2016; 17: 127","DOI":"10.1186\/s12882-016-0337-0"},{"key":"10.3238\/arztebl.m2025.0131_ref86","doi-asserted-by":"crossref","unstructured":"Charytan DM, Himmelfarb J, Ikizler TA, et al.: Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): A randomized, placebo-controlled, multiple dosage trial. Kidney Int 2019; 95: 973\u201382","DOI":"10.1016\/j.kint.2018.08.034"},{"key":"10.3238\/arztebl.m2025.0131_ref87","doi-asserted-by":"crossref","unstructured":"Matsumoto Y, Mori Y, Kageyama S, et al.: Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014; 63: 528\u201336","DOI":"10.1016\/j.jacc.2013.09.056"},{"key":"10.3238\/arztebl.m2025.0131_ref88","doi-asserted-by":"crossref","unstructured":"Hammer F, Malzahn U, Donhauser J, et al.: A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int 2019; 95: 983\u201391","DOI":"10.1016\/j.kint.2018.11.025"},{"key":"10.3238\/arztebl.m2025.0131_ref89","doi-asserted-by":"crossref","unstructured":"Ingelfinger JR, Rosen CJ: Finerenone\u2014halting relative hyperaldosteronism in chronic kidney disease. N Eng J Med 2020; 383: 2285\u20136","DOI":"10.1056\/NEJMe2031382"},{"key":"10.3238\/arztebl.m2025.0131_ref90","doi-asserted-by":"crossref","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383: 2219\u201329","DOI":"10.1056\/NEJMoa2025845"},{"key":"10.3238\/arztebl.m2025.0131_ref91","doi-asserted-by":"crossref","unstructured":"Filippatos G, Anker SD, Agarwal R, et al.: Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation 2021; 143: 540\u201352","DOI":"10.1161\/CIRCULATIONAHA.120.051898"},{"key":"10.3238\/arztebl.m2025.0131_ref92","doi-asserted-by":"crossref","unstructured":"Tamargo J, Kjeldsen KP, Delp\u00f3n E, et al.: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother 2022; 8: 406\u201319","DOI":"10.1093\/ehjcvp\/pvac005"},{"key":"10.3238\/arztebl.m2025.0131_ref93","doi-asserted-by":"crossref","unstructured":"Bramlage P, Sims H, Minguet J, Ferrero C: The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk. Eur J Prev Cardiol 2017; 24: 297\u2013310","DOI":"10.1177\/2047487316674817"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:53:27Z","timestamp":1767686007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":93,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0131","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}